Glembatumumab vedotin

N/A

Report date: 2024/02/05 13:54:49

Base Information

Drug NameGlembatumumab vedotin
Drug Alias Name维格巴妥人单抗GlembaGlembatumumabum vedotinum维汀-格仑妥木单抗Glembatumumab vedotina +[9] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionTubulin polymerisation inhibitorsTransmembrane glycoprotein NMB modulators
TargetsTubulinTransmembrane glycoprotein NMB
Therapy Area/IndicationsUveal melanomaSkin MelanomaSolid tumours +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[10] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCelldex Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute
Inactive CompaniesCuragen CorporationCelldex TherapeuticsPrecog Llc +[4] 
Active IndicationsOsteosarcoma
Inactive IndicationsUveal melanomaSkin MelanomaSolid tumours +[7] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG